Werewolf Therapeutics (HOWL) Net Margin (2022 - 2026)

Werewolf Therapeutics (HOWL) posted quarterly Net Margin of 33.14% for Q2 2026, up 100.03% on a QoQ basis from 126720.0% in Q4 2024.

Werewolf Therapeutics (HOWL) Net Margin (2022 - 2026) Analysis & Trends

Werewolf Therapeutics has reported Net Margin for 4 years, with the latest figure at 33.14% in Q2 2026.

Net Margin for Q2 2026 came in at 33.14%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was 165.91% (up 48002075.0% YoY), and the FY2024 annual result was 7088.26%, down 668639.0% from the prior year.
Net Margin grew to 33.14% in Q2 2026, from 126720.0% in the prior quarter.
Over five years, Net Margin peaked at 33.14% in Q2 2026 and troughed at 126720.0% in Q4 2024.
A 4-year average of 12042.99% and a median of 243.64% in 2023 frame the typical range for Net Margin.
The widest annual swing landed in 2023, when Net Margin jumped 28906 bps; it then tumbled 12592073 bps in 2024.
A 4-year view of Net Margin shows it stood at 163.81% in 2022, then tumbled by 388 bps to 799.27% in 2023, then tumbled by 15755 bps to 126720.0% in 2024, then surged by 100 bps to 33.14% in 2026.
Per Business Quant data, the three most recent Net Margin figures were 33.14% in Q2 2026, 126720.0% in Q4 2024, and 1601.84% in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Werewolf Therapeutics	20.90 Mn	20.90 Mn	-	33.14%

Download Data